Srdan Verstovsek, MD, PhD, discusses the data seen in the phase 2 trial of CPI-0610 with or without ruxolitinib in patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, medical oncologist, and professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the data seen in the phase 2 trial (NCT02158858) of CPI-0610 with or without ruxolitinib (Jakafi) in patients with myelofibrosis.
There was an 80% response rate in 15 of these patients after 3 months of follow-up which was presented at the 2019 American Society of Hematology Annual Meeting. The trial accrued more patients and at the time of the next follow-up, the response rate was 72%. Verstovsek says this suggests differences in the patient’s underlying baseline characteristics or a novel problem that has not been seen before. The difference in response rates was small.
The prolongation of duration time with more patients over 6 months has decreased the overall response rate to about 63%, which may be related to the time frame or patient characteristics, according to Verstovsek. He thinks these types of details would be helpful to analyze in the future. The rate of 63% was still a good response for this therapy since, in similar patient populations, the response rate is usually about 50% to 60%. CPI-0610 is still valuable to pursue with a larger group of patients who are more diverse in baseline characteristics to get a better idea of the response to this agent.